Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Michael Geissler,Jorge Riera-Knorrenschild,Uwe M. Martens,Swantje Held,Jobst Greeve,Axel Florschütz,Thomas Jens Ettrich,Stephan Kanzler,Andrea Tannapfel,Volker Heinemann,Anke Reinacher-Schick,Thomas Seufferlein,Swen Wessendorf,Dominik Paul Modest

Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

2019

Michael Geissler
Jorge Riera-Knorrenschild
Uwe M. Martens
Swantje Held
Jobst Greeve
Axel Florschütz
Thomas Jens Ettrich
Stephan Kanzler
Andrea Tannapfel
Volker Heinemann
Anke Reinacher-Schick
Thomas Seufferlein
Swen Wessendorf
Dominik Paul Modest

3511Background: This trial evaluated activity and safety of mFOLFOXIRI + panitumumab vs FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients. The final primary endpoint was presented at AS...

Keywords:

FOLFOXIRI
Wild type
Oncology
Colorectal cancer
Panitumumab
Pathology
Internal medicine
Medicine
first line treatment
in patient
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations